ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 345

Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population

Proton Rahman1, Denis Choquette2, William G. Bensen3, Majed M. Khraishi4, Isabelle Fortin5, Andrew Chow6, Maqbool K. Sheriff7, Julie Vaillancourt8, John S. Sampalis8, Susan M. Otawa9, Allen J. Lehman9 and May Shawi10, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 3Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 4Nexus Clinical Research, St John's, NF, Canada, 5Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 6University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8JSS Medical Research, Montreal, QC, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Enthesitis, extraarticular manifestations, psoriatic arthritis and spondylarthropathy

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

To determine the point prevalence of peri-articular manifestations (PAMs) in psoriatic arthritis (PsA) patients treated with anti-TNF in a real-world, Canadian, routine clinical practice setting.

Methods:

BioTRAC is an ongoing, prospective, registry of patients initiating treatment for PsA, AS or RA with infliximab or golimumab as first biologics or after having been treated with a biologic for < six months. In this analysis of data collected since 2010, 91 PsA patients with available baseline information on PAMs were included: enthesitis (n=62), dactylitis of hands (n=76) or feet (n=77), nail pitting of hands (n=76) or feet (n=75).

Results:

Baseline characteristics included mean (SD) age, disease duration of 48.7 (10.3), 6.5 (6.9) years, respectively, and mean (SD) DAS28-CRP score of 4.1 (1.2).

Among all patients at baseline, 50 (54.9%) had a PAM. Dactylitis (feet – 39.0%; hands – 15.8%) was the most common PAM followed by enthesitis (27.4%), and nail pitting (hands – 26.3%; feet – 24.0%). Patients with enthesitis had greater mean (SD) DAS28-CRP (4.7 (1.0) vs. 3.9 (1.3); P=0.042) and HAQ-DI (1.33 (0.73) vs. 0.94 (0.77); P=0.076) compared to patients without enthesitis. However, mean (SD) age (47.0 (10.0) vs. 48.8 (9.5) years; P=0.544), disease duration (6.1 (7.3) vs. 6.0 (6.2) years; P=0.937), and morning stiffness (52.6 (43.4) vs. 56.7 (45.2) min; P=0.750) were comparable between-groups. Among patients with/without dactylitis, baseline mean (SD) parameters were: age (46.8 (12.5) vs. 50.5 (8.9) years; P=0.145), disease duration (6.2 (6.8) vs. 7.0 (7.7) years; P=0.666), DAS28-CRP (4.5 (0.9) vs. 4.0 (1.4); P=0.105), HAQ-DI (1.08 (0.69 vs. 1.09 (0.69); P=0.925), and morning stiffness (73.2 (44.8 vs. 51.6 (42.0) min; P=0.033). 

Upon six months of treatment, significant improvement in all disease activity parameters studied was observed. Six-month PAM data were available for 50 (54.9%) patients. Overall, the prevalence of PAMs decreased from baseline to six months post-treatment (P=0.001). Among patients with available six-month information that had a PAM at baseline (n=33), (48.5%) did not present any manifestation after six months. The incidence of new PAMs by six months was minimal.

Conclusion:

In this Canadian real-world cohort of PsA patients, a high prevalence of PAMs was observed at treatment initiation. Patients with enthesitis or dactylitis had increased disease activity compared to patients without PAMs. Infliximab or golimumab treatment for six months was associated with a significant improvement in patient parameters and reduction in the prevalence of PAMs.


Disclosure:

P. Rahman,

Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,

5,

Amgen, Abbott, BMS, Merck, Pfizer, Janssen, Hoffman-La Roche, UCB, Novartis, Sanofi-Aventis,

9;

D. Choquette,
None;

W. G. Bensen,
None;

M. M. Khraishi,

Hoffman-La Roche Canada, Amgen and Pfizer Canada, and Abbott Canada.,

2;

I. Fortin,
None;

A. Chow,
None;

M. K. Sheriff,
None;

J. Vaillancourt,

JSS ,

3;

J. S. Sampalis,
None;

S. M. Otawa,

Janssen Canada,

3;

A. J. Lehman,

Janssen Canada,

3;

M. Shawi,

Janssen Canada,

3.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-peri-articular-manifestations-enthesitis-and-dactylitis-and-disease-activity-in-psoriatic-arthritis-patients-impact-of-treatment-with-tnf-inhibitors-in-a-real-world-canadian-populatio/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.